Altimmune Newsroom

Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Hansa Biopharma AB (SE:HNSA)

TipRanksOct 9 05:02 ET

Piper Sandler Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsOct 4 08:31 ET

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)

TipRanksOct 4 08:15 ET

JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24

Moomoo NewsSep 30 10:31 ET

JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24

Moomoo NewsSep 11 01:32 ET

JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24

Moomoo NewsSep 10 17:32 ET

Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements

TipRanksSep 10 16:37 ET

Altimmune Analyst Ratings

BenzingaAug 22 13:40 ET

H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsAug 22 12:32 ET

Altimmune Analyst Ratings

BenzingaAug 12 14:44 ET

Buy Rating on Altimmune: Pemvidutide's Market Potential in Obesity and Beyond

TipRanksAug 12 12:42 ET

Evercore ISI Remains a Buy on Altimmune (ALT)

TipRanksAug 9 09:55 ET

Buy Rating Affirmed for Altimmune as Pemvidutide Poised to Lead NASH Treatment Market

TipRanksAug 8 18:00 ET

B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Announces Target Price $20

Moomoo NewsAug 2 07:31 ET

Altimmune Analyst Ratings

BenzingaJun 21 13:52 ET

Buy Rating Affirmed for Altimmune on Promising Pemvidutide Data and Market Position

TipRanksMay 30 02:09 ET

Buy Rating Justified by Altimmune's Promising Pemvidutide Efficacy in NASH Treatment

TipRanksMay 21 18:10 ET

Altimmune Analyst Ratings

BenzingaMay 14 07:52 ET

Buy Rating Justified: Altimmune's Pemvidutide Shows Best-in-Class Potential for Obesity and MASH

TipRanksMay 14 06:25 ET

Buy Rating Affirmed for Altimmune on Pemvidutide's Potential and Strategic Advancements

TipRanksMay 10 14:30 ET